A Response-Adapted Clinical Trial of Weekly Carfilzomib With or Without Rituximab for Waldenström's Macroglobulinemia and Marginal Zone Lymphoma
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Rituximab (Primary)
- Indications Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 09 Jul 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 26 Dec 2017 Status changed from not yet recruiting to recruiting.